In wonderful news for prostate cancer research, we’re proud to announce that Prof Lisa Horvath, Director of Research at the Chris O’Brien Lifehouse, has been awarded a $1.9 million Investigator Grant from the National Health and Medical Research Council (NHMRC). The grant will fund Prof Horvath’s internationally recognised research into new treatments for prostate cancer and ways to ensure that treatment is as effective as possible.
Prof Horvath leads a team of researchers who are looking into how biomarkers can be used to personalise and hone treatment for men with advanced prostate cancer.
Prostate cancer is the most commonly diagnosed cancer for men in Australia. Last year more than 3,300 men died from the disease. Prof Horvath and her multidisciplinary research team have already made important discoveries in the use of biomarkers to predict which patients will respond to chemotherapy.
This program aims to assess and validate the ability of blood-based molecular markers to predict an individual patient’s response to different treatments and develop new drug strategies based on biological endpoints. Being able to tailor the treatment to the patient allows oncologists to ensure the patient is getting the most effective treatment as well as avoiding unnecessary treatment that is unlikely to work. In particular, Prof Horvath’s team is investigating the role of circulating lipids and how to develop personalised metabolic treatment strategies to complement current chemotherapy and hormonal therapies.
“This significant investment can only further strengthen Australia’s reputation as a world leader in cancer research and is the fruit of some very hard work by a multidisciplinary, multi-institutional collaborative group of researchers,” said Prof Horvath.
This prestigious government grant is a wonderful acknowledgement of the potential impact of this research and of the efforts of every member of the team.
Congratulations Prof Horvath and team, we are immensely proud of the work you are doing to improve treatment options for our patients.